Administration Case Report With EXPAREL

This case report represents the individual experience of Dr Nirav H. Amin and is intended to demonstrate his methodology for using EXPAREL in a specific orthopedic procedure. Pacira Pharmaceuticals, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations when selecting the dose for a specific procedure. EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

CASE INFORMATION

<table>
<thead>
<tr>
<th>Physician Name</th>
<th>Nirav H. Amin, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliation</td>
<td>Associate Professor, Sports Medicine and Adult Knee Reconstruction Loma Linda University</td>
</tr>
<tr>
<td>Surgical Case Performed</td>
<td>Left unstable intertrochanteric hip fracture fixation</td>
</tr>
<tr>
<td>Inpatient or Outpatient Procedure</td>
<td>Inpatient</td>
</tr>
</tbody>
</table>

PATIENT CHARACTERISTICS

| Gender | Female |
| Age    | 89 years |
| Patient History and Characteristics | The patient sustained a hip fracture as the result of a fall. She was using a rolling walker before the fall due to balance concerns |
| Pathology | Left unstable intertrochanteric hip fracture; determined that intramedullary nail fixation would allow for greatest healing potential |

PROCEDURAL DETAILS

| Incision Size | 5 cm for nail entry site 4 cm for hip screw site 1 cm for each distal locking site |
| Preoperative Analgesics Used | IV 1 g acetaminophen IV 1 g tranexamic acid |
| Intraoperative Analgesics Used | 50 mcg fentanyl 120 mL of expanded EXPAREL |

Dose of EXPAREL and Total Volume Used

![Image of EXPAREL, Bupivacaine HCI 0.5%, Normal Saline, totaling 120 mL.](image.png)

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg. EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.

Bupivacaine HCI may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCI to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physicochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine HCI, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
In this procedure, Dr. Amin determined that a total volume of 120 mL would be needed to cover the surgical sites. He expanded 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 80 mL of normal saline and admixed the solution with 20 mL of 0.5% bupivacaine HCl. Dr. Amin added bupivacaine HCl to provide short-term local analgesia in the postanesthesia care unit that overlapped with the long-term local analgesia provided by EXPAREL.

For this procedure, Dr. Amin divided the injectate into six 20-mL syringes using a 22-gauge needle and infiltrated as follows:

**NAIL ENTRY SITE**
- Syringe #1: Soft tissue and periosteum
- Syringe #2: Superior and inferior to nail entry site, into periosteum

**HIP SCREW SITE**
- Syringe #3: Anterior and posterior to hip screw site, into periosteum
- Syringe #4: Superior to hip screw site, into periosteum

**DISTAL INTERLOCK SITES**
- Syringe #5: Fracture hematoma site
- Syringe #6: Soft tissue and periosteum of distal interlock sites

**FRACUTURE SITE**
- Syringe #4: Fracture hematoma site
- Syringe #5: Fracture hematoma site

Avoid injecting posteriorly due to the proximity to the sciatic nerve and other neurovascular structures.

If there are fewer than 2 distal locking screws, use 10 mL at the distal interlock site and infiltrate remainder of syringe #6 into either the hip screw site or the nail entry site.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
PROPER TECHNIQUE IS CRUCIAL FOR ANALGESIC COVERAGE

Dr Amin infiltrated EXPAREL® (bupivacaine liposome injectable suspension) into all tissue layers using a moving needle technique. With a moving needle technique, the injections were spread in a fan-like pattern and occurred as the needle was both inserted and withdrawn to maximize the coverage area. This technique was systematically and meticulously repeated at each injection site, with overlapping diffusion of EXPAREL to ensure there were no gaps in analgesic coverage.

Watch Dr Amin infiltrate with EXPAREL at www.EXPAREL.com

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

WARNINGS AND PRECAUTIONS SPECIFIC TO EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

WARNINGS AND PRECAUTIONS FOR BUPIVACAINE-CONTAINING PRODUCTS

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Disclosure: Dr Amin is a paid consultant for Pacira Pharmaceuticals, Inc.